MRVI Maravai LifeSciences Holdings

Maravai LifeSciences Announces March 2021 Investor Conference Schedule

Maravai LifeSciences Announces March 2021 Investor Conference Schedule

SAN DIEGO, March 01, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in two upcoming virtual investor conferences.

On March 3, 2021, Carl Hull, Chief Executive Officer, is scheduled to present at the Cowen Health Care Conference at 10:20 a.m. PT.

On March 23, 2021, Hull will participate in a fireside chat at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum at 8:30 a.m. PT.

A live webcast of the presentations will be available to all interested parties on the Maravai Lifesciences investor relations website at . An archived version of the webcast will be available a few hours following the completion of each event on the Maravai investor relations website.

About Maravai

Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis, bioprocess impurity detection and analysis, and protein labeling and detection to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.

For more information about Maravai LifeSciences, visit .



Contact Information:
Media Contact: Sara Michelmore
MacDougall
 
 

Investor Contact: Deb Hart
Maravai LifeSciences
 7
 
EN
01/03/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Maravai LifeSciences Holdings

 PRESS RELEASE

Maravai LifeSciences Appoints Rajesh Asarpota as Chief Financial Offic...

Maravai LifeSciences Appoints Rajesh Asarpota as Chief Financial Officer SAN DIEGO, June 25, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that Rajesh “Raj” Asarpota has been appointed Executive Vice President (EVP) and Chief Financial Officer (CFO), effective June 30, 2025. He will succeed Kevin Herde, who is transitioning to an advisory role on the same date to support an effective transition.  “We thank Kevin for his commitment to Maravai and his...

 PRESS RELEASE

Maravai LifeSciences Appoints Bernd Brust as Chief Executive Officer a...

Maravai LifeSciences Appoints Bernd Brust as Chief Executive Officer and Member of its Board of Directors SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the appointment of Bernd Brust as Chief Executive Officer (CEO) and a member of the Board of Directors, effective immediately. Mr. Brust succeeds William “Trey” Martin III in these roles. “This leadership transition reflects Maravai’s commitment to accelerating innovation, execut...

 PRESS RELEASE

CORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report

CORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- This release corrects and replaces the version distributed earlier today at 16:05 ET. The original version included the ...

 PRESS RELEASE

Maravai LifeSciencesReleases 2024 Sustainability Report

Maravai LifeSciencesReleases 2024 Sustainability Report Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of lifescience reagents and services to researchers and biotech ...

 PRESS RELEASE

Maravai Lifesciences Reports First Quarter 2025 Financial Results

Maravai Lifesciences Reports First Quarter 2025 Financial Results SAN DIEGO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2025, together with other business updates. Financial Highlights: Quarterly revenue of $46.9 million, Net loss of $(52.9) million (including a goodwill impairment of $12.4 million), and Adjusted EBITDA of $(10.5) million; andRevenue for the full y...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch